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ABSTRACT Transgenic overexpression (40- to 100-fold)
of the wild-type human b2-adrenergic receptor in the hearts
of mice leads to a marked increase in cardiac contractility,
which is apparently due to the low level of spontaneous (i.e.,
agonist-independent) activity inherent in the receptor. Here
we report that transgenic mice expressing a mutated consti-
tutively active form of the receptor (CAM) show no such
phenotype, owing to its modest expression (3-fold above
endogenous cardiac b-adrenergic receptor levels). Surpris-
ingly, treatment of the animals with a variety of b-adrenergic
receptor ligands leads to a 50-fold increase in CAM b2-
adrenergic receptor expression, by stabilizing the CAM b2-
adrenergic receptor protein. Receptor up-regulation leads in
turn to marked increases in adenylate cyclase activity, atrial
tension determined in vitro, and indices of cardiac contractil-
ity determined in vivo. These results illustrate a novel mech-
anism for regulating physiological responses, i.e., ligand-
induced stabilization of a constitutively active but inherently
unstable protein.
Several naturally occurring and artificially created point mu-
tations of G protein-coupled receptors lead to an abrogation
of intramolecular interactions, which normally constrain re-
ceptors to an inactive state (1, 2). This results in constitutive
or agonist-independent activity of the receptors. Studies of
such constitutively active mutant (CAM) receptors have re-
vealed that in many respects their properties mimic those of the
activated state of the normal receptors. In several cases they
initiate human diseases (3–7). It was also shown in vitro that
such a CAM b2-adrenergic receptor possesses increased con-
formational f lexibility, which results not only in constitutive
activity of the receptor but in marked instability (8). To assess
the in vivo consequences of these unique properties, we created
transgenic mice overexpressing the CAM b2-adrenergic re-
ceptor in the heart.
EXPERIMENTAL PROCEDURES
Construction of the Transgenic Mouse Line. The cDNA
encoding the CAM b2-adrenergic receptor (1) was spliced to
the a-myosin heavy chain gene promoter and the simian virus
40 intronytermination sequences, as described (9). Mouse eggs
were injected with the linearized DNA construct and im-
planted in pseudo-pregnant females (strain C57 Black; geno-
type B6SJF1yJ1). Offspring were selected for the presence of
the transgene-specific simian virus 40 sequence.
In Vitro Assays of Receptor Function. Particulate fractions
were prepared from the hearts as described (9). The hearts
were homogenized in ice-cold buffer (50 mM Hepes, pH
7.2y150 mM NaCly5 mM EDTA). The 800 g supernatants
were spun twice at 38,0003 g. The final pellet was resuspended
in 50 mM Hepes (pH 7.2)y12 mM MgCl2. Total b-adrenergic
receptor binding was measured at 378C for 45 min using 300
pM 125I-CYP in 50 mMHepes (pH 7.2), 5 mM EDTA, 0.1 mM
ascorbic acid, and included 2 mM propranolol for nonspecific
binding (1). b1 and b2 subtype proportions were determined by
competition with varying doses of the b2-selective ligand ICI
118,551 (10).
Adenylate cyclase activity was determined as described (9).
Heart particulate preparations were pre-incubated with b-ad-
renergic ligands for 5 min at 378C in 20 mM Hepes (pH 7.2),
4.5 mMMgCl2, 2.7 mMphosphoenolpyruvate, 53mMGTP, 0.1
mM cAMP, 150 mM ATP, 20 unitsyml myokinase, 4 unitsyml
pyruvate kinase, 0.1 mM ascorbic acid. The radioactive tracer
([a-32P]ATP, '1 mCi per sample, 1 Ci 5 37 GBq; New
England Nuclear) was added and the reactions allowed to
proceed for another 10 min at 378C, after which they were
quenched on ice. Total adenylate cyclase activity was deter-
mined using 10 mM NaF. [32P]cAMP was separated as de-
scribed (9).
Determination of Atrial Tension. Two- to four-month-old
animals were treated for 91 hr with ICI 118,551 (0.7 mgykgyhr)
or vehicle (50% dimethylsulfoxidey50% saline) using osmotic
minipumps (Alzet, Palo Alto, CA) implanted subcutaneously
under anesthesia (10). The hearts were removed 6–12 hr after
the pumps had run out, to allow for four biological half-lives
of the ligand to elapse. Left atria (2–4 mg) were excised from
the hearts and suspended in carbogenated modified Kreb’s
bicarbonate solution supplemented with 0.1 mM ascorbic acid,
0.1 mM cocaine, 0.4 mM corticosterone, and 3 mM phentol-
amine (9). They were paced at optimal frequency for isometric
tension development (3.2 Hz), 3 msec pulse duration, voltage
at threshold 120%, as described (9). Agonist-induced re-
sponses were measured after tension reached a plateau (2–4
min).
Determination of in Vivo Left Ventricular (LV) Function.
Twelve hours after the pumps had run out (see above),
hemodynamic parameters were measured in live anesthetized
mice (10). After anesthesia, mice were intubated and con-
nected to a rodent ventilator. Either carotid artery was can-
nulated with a flame-stretched PE-50 catheter connected to a
pressure transducer. Following bilateral vagotomy, the chest
was opened and a 1.8 Fr high-fidelity micromanometer cath-
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eter was inserted into the left atrium, advanced through the
mitral valve, and secured in the left ventricle. Hemodynamic
measurements were recorded at baseline and 45–60 sec after
injection of incremental doses of isoproterenol in a cannulated
jugular vein. Doses of isoproterenol were specifically chosen to
maximize the contractile response but limit the increase in
heart rate. Continuous high fidelity LV and fluid filled aortic
pressure were recorded simultaneously at baseline and 45–60
sec after each dose of agonist on an 8-channel chart recorder
and in digitized form at 2000 Hz for later analysis. Parameters
measured were heart rate, aortic pressure, LV systolic and end
diastolic pressure, and the maximal and minimal first deriva-
tive of LV pressure (LV dPydtmax per min). Ten sequential
beats were averaged for each measurement.
RESULTS AND DISCUSSION
The CAM b2-adrenergic receptor (1) was expressed under the
control of the a-myosin heavy chain promoter. This promoter
leads to expression of the transgene in the atrium during
embryonic and adult life, and expression in the ventricular
myocardium after birth (9). Descendants of two founders were
studied between 2 and 4 months of age, when expression of the
transgene was constant (data not shown). b-adrenergic recep-
tors are expressed at 59 6 12 fmolymg membrane protein
(mean 6 SEM) in membranes prepared from the hearts of
nontransgenic animals (n 5 8), with the b1 and b2 subtypes
accounting for '75% and '25%, respectively (10). In trans-
genic animals, total myocardial receptor density was 209 6 11
fmolymg (n5 12, Fig. 1A), and the increase was accounted for
by the exogenous b2-adrenergic receptor. Expression of the
transgene did not affect the expression of the endogenous
b1-adrenergic receptor (nontransgenic littermates: 45 6 11
fmolymg membrane protein, n 5 6; transgenic animals: 53 6
6 fmolymg membrane protein, n 5 6).
In nontransgenic mice, the agonist isoproterenol stimulates
plasmalemmal adenylate cyclase 2- to 3-fold. Expression of the
transgenic CAM b2-adrenergic receptor leads to an increase in
maximal agonist-evoked adenylate cyclase activity in cardiac
particulate fractions (Fig. 1B). Thus, both expression of the
transgene and functional coupling of the exogenous b2-
adrenoreceptors can be demonstrated in these transgenic
animals. However, no increase in agonist-independent adenyl-
ate cyclase activity was observed, presumably because of the
low expression level of the transgene.
Biological Effects of in Vivo Antagonist Infusion. Previous
studies in cultured cells have shown that the CAM b2-
adrenoreceptor is poorly expressed and spontaneously down-
regulated. This down-regulation can be alleviated by inclusion
of b-adrenergic ligands in the culture medium, leading to an
'2-fold increase in expression levels (8, 11). To examine
whether such a regulatory effect could be observed in vivo, we
infused transgenic animals with the inverse agonist ICI 118,551
for 7 or 4 days using subcutaneous osmotic minipumps (11).
After the pumps had run out, b-adrenergic receptor function
was assessed in vitro and in vivo. Receptor expression was
dramatically increased, to 6.96 0.8 pmolymg (n5 8, Fig. 1A),
an '50-fold overexpression. This increase was due entirely to
up-regulation of the transgene, and the endogenous b1-
adrenoreceptor was not modulated (54 6 12 fmolymg mem-
brane protein, n 5 5). ICI 118,551 treatment of nontransgenic
animals did not result in any change of b-adrenergic receptor
density in the myocardium or the lungs (data not shown).
ICI 118,551 treatment also led to an increase in basal
adenylate cyclase, to levels comparable with that of agonist-
activated cyclase in vehicle-treated transgenic animals (Fig.
1B). However, there was no change in either total NaF-
stimulated adenylate cyclase activity (nontransgenic: 70 6 8
pmol cAMP per mg membrane protein per min, n 5 6;
vehicle-treated transgenic: 68 6 10 pmol cAMP per mg
membrane protein per min, n 5 6; ICI 118,551-treated trans-
genic: 886 24 pmol cAMP per mg membrane protein per min,
n 5 5), or G protein-coupled receptor kinase 2 immunoreac-
tivity (data not shown) (10).
Atrial tension was measured on excised left atria. In non-
transgenic and vehicle-treated transgenic animals, baseline
tension was comparable, and was stimulated '2-fold by a
maximal concentration of the agonist isoproterenol (100 nM;
Fig. 2). By contrast, the infusion of ICI 118,551 in transgenic
animals produced a significant elevation of baseline tension
when compared with nontransgenic and vehicle-treated trans-
genic animals. This elevated baseline tension was not signifi-
cantly increased further by the addition of isoproterenol, and
was comparable with the agonist-stimulated tension of non-
transgenic and vehicle-treated transgenic preparations (Fig.
2). ICI 118,551 treatment of nontransgenic animals did not
alter baseline or isoproterenol-stimulated tension (data not
shown).
To determine whether treatment with ICI 118,551 alters the
in vivo cardiac phenotype in transgenic mice overexpressing
the mutant b2-adrenergic receptor, cardiac catheterization was
used to measure contractile function in live anesthetized mice.
Continuous measurements of LV pressure and the maximal
first derivative of LV pressure (dPydtmax) were recorded
FIG. 1. (A) b2-adrenergic receptor density in the myocardium. NT,
nontransgenic littermates (n5 8); CAM vehicle, vehicle-treated CAM
b2-adrenergic receptor transgenic animals (n 5 12); CAM ICI, ICI
118,551-treated transgenic animals (n5 8). Shown are means6 SEM.
pp, P , 0.01, CAM ICI vs. CAM vehicle; p, P , 0.05, CAM vehicle
vs. NT (Student’s t test). (B) Adenylate cyclase activity in myocardial
particulate fractions. Basal, no added drug; Iso, 100 mM isoproterenol.
NT, n 5 6; CAM vehicle, n 5 6; CAM ICI, n 5 5. p, P , 0.05, Iso
vs. Basal; †, P , 0.05, Iso CAM vehicle vs. Iso NT; ††, P , 0.05, Iso
CAM ICI vs. Iso CAM vehicle; ‡, P , 0.05, Basal CAM ICI vs. Basal
CAM vehicle; Iso CAM vehicle vs. Basal CAM ICI, P 5 n.s.
FIG. 2. Left atrial tension. Baseline, saline. Iso, 100 nM isopro-
terenol. NT, CAM vehicle, CAM ICI as in Fig. 1. p, P , 0.05, Iso vs.
Baseline. †, P, 0.05, CAM ICI Baseline vs. CAM Baseline (Student’s
t test).
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before and after progressive injections of isoproterenol. CAM
b2-adrenergic receptor mice pre-treated with ICI 118,551
showed a 45% increase in basal dPydtmax, which was accen-
tuated with a low-dose isoproterenol injection. Myocardial
relaxation as measured by LV dPydtmin was also significantly
enhanced by treatment in the transgenic mice (data not
shown). ICI 118,551 treatment did not alter baseline LV
systolic pressure. However, the marked increase in contractile
function with isoproterenol (50 pg) in the treated CAM
b2-adrenergic receptor mice was associated with a significantly
higher LV systolic pressure (Fig. 3B). In contrast, treatment
with ICI 118,551 had no significant effect in nontransgenic
mice (Fig. 3 C and D).
Thus, ligand-induced up-regulation of the CAM b2-
adrenoreceptor leads to constitutive activation of the adren-
ergic signaling cascade in the heart. This constitutive activation
is observed at lower expression levels than those previously
obtained with the wild-type b-adrenergic receptor (20–40
pmolymg) (9), consistent with the higher basal activity of the
mutated receptor.
Biochemical Basis of the Receptor Up-Regulation. We in-
fused transgenic animals with a variety of b-adrenergic recep-
tor ligands, ranging in efficacy from inverse agonists to full
agonists. Inverse agonists (nadolol, ICI 118,551) and antago-
nists (propranolol, alprenolol, pindolol) were found to up-
regulate the transgenic receptor to a similar extent (Fig. 4A,
compounds 1–5). Atenolol (2 mgykgyhr), a preferential b1-
adrenoreceptor antagonist, produced negligible up-regulation
([R] 5 315 6 40 fmolymg, n 5 4), indicating that the
up-regulation of the transgenic b2- adrenoreceptor is not
mediated by the endogenous b1-subtype adrenoreceptor. A
single bolus dose of ICI 118,551 did not result in receptor
up-regulation (data not shown), and the continued presence of
ICI 118,551 in the circulation was necessary for the mainte-
nance of receptor overexpression. Indeed, when the 4-day
infusion with ICI 118,551 was followed by a 4-day ‘‘recovery’’
period, myocardial receptor density was down to 1 6 0.5
pmolymg (n 5 4).
FIG. 3. In vivo assessment of LV contractile function. Measured
parameters are shown at baseline and after progressive injections of
isoproterenol. Hemodynamic measurements were performed in trans-
genic mice overexpressing the CAM b2-adrenergic receptor (A and B:
ICI 118,551 treated, n5 11; vehicle treated, n5 10) and nontransgenic
littermate controls (C and D: ICI 118,551 treated, n 5 11; vehicle
treated, n 5 9). Data are expressed as mean 6 SEM. ICI 118,551-
treated vs. vehicle-treated data were compared using a two-way
repeated-measure ANOVA. Post-hoc comparison of differences in
mean values between the groups at a specific dose were conducted with
a Newman–Keuls test; p, P , 0.01. A significant between-group main
effect in response to isoproterenol was found for LV dPydtmax (A; P,
0.05). The pattern of change between groups was statistically different
for LV dPydtmax (A; P , 0.0001) and LV systolic pressure (B; P ,
0.05). ICI 118,551 treatment of animals did not alter the measured
hemodynamic parameters in nontransgenic littermate controls (C and
D). LV end diastolic pressure was not statistically different between
groups at baseline (4.46 0.8 vs. 5.36 0.6 mmHg in ICI 118,551-treated
vs. vehicle-treated transgenic animals, respectively; 4.9 6 0.6 vs. 4.0 6
0.7 mmHg in ICI 118,551-treated vs. vehicle-treated littermate con-
trols, respectively). Pretreatment with ICI 118,551 did not alter heart
rate in transgenic mice (484 6 33 vs. 525 6 24 beats per min mmHg
in ICI 118,551-treated vs. vehicle-treated animals, P 5 ns), or in
nontransgenic littermate controls (3836 21 vs. 3706 25 beats per min
in ICI 118,551-treated vs. vehicle-treated animals, P 5 ns).
FIG. 4. Effect of in vivo treatment with adrenoreceptor ligands on
CAM b2-adrenergic receptor levels and transgene expression. (A)
Receptor levels in cardiac particulate preparations. The intrinsic
activity of drugs at the CAM receptor was assessed in vitro at the level
of adenylate cyclase in myocardial particulate preparations. Intrinsic
activity (IA) was defined using untreated CAM transgenic animals
(n 5 2–4) as the fraction of adenylate cyclase activity evoked by the
drug, compared with the reference full agonist isoproterenol (IA5 1)
and the basal activity (IA 5 0). Negative intrinsic activities (inverse
agonists) were assessed with ICI 118,551-treated up-regulated CAM
animals ([R]5 46 1 pmolymg, n5 4), with IA5 0 for basal and IA5
21 for maximal inhibition of basal, to the level of nontransgenic basal
activity (see Fig. 1B). Nadolol and ICI 118,551 were used at 1 mM, and
all other drugs were used at 20 3 Kd (1). All reactions included 300
nM CGP 20712A, which blocks the endogenous b1-adrenergic recep-
tor subtype selectively. 1, ICI 118,551 (0.7 mgykgyhr); 2, nadolol (1.2
mgykgyhr); 3, propranolol (0.4 mgykgyhr); 4, alprenolol (0.4 mgykgy
hr); 5, pindolol (0.4 mgykgyhr); 6, dichloroisoproterenol (1.2 mgykgy
hr); 7, ephedrine (0.3 mgykgyhr); 8, dobutamine (1 mgykgyhr); 9,
norepinephrine (0.3 mgykgyhr); 10, epinephrine (0.1 mgykgyhr); 11,
isoproterenol (0.1 mgykgyhr). Crosshatched bar, untreated CAM
transgenic. Shown are mean receptor densities 6 SEM of 4–10
animals. (B) mRNA levels following drug treatment. NT, CAM
vehicle, and CAM ICI as in Fig. 1. Total RNA was extracted from
myocardial tissue (Biotecx Laboratories, Houston) and analyzed by
Northern blotting. Shown are two representative lanes for each animal
group (5 mg RNA per lane). The blots were probed with a simian virus
40 sequence, which is unique to the transgenic DNA construct (CAM,
Upper), stripped and reprobed with the cDNA encoding glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) as an internal quantity
control (Lower) (12). Arrowheads, relative location of the 18S ribo-
somal RNA. Northern blots (3–4 animals per group) were also
quantified on a PhosphorImager (Molecular Dynamics). When nor-
malized to the amount of GAPDH mRNA, the transgene mRNA was
not significantly increased by the ICI 118,551 treatment (data not
shown).
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In contrast to inverse agonists and antagonists, agonists did
not cause significant up-regulation (compounds 7–11),
whereas dichloroisoproterenol, a weak partial agonist (com-
pound 6), led to intermediate receptor levels. Thus, the
magnitude of the up-regulation in vivo seems inversely related
to drug efficacy, although it does not discriminate between
inverse agonists (e.g., nadolol) and antagonists (e.g., alpreno-
lol).
Reserpine perfusion was previously shown to deplete.98%
of catecholamine stores in the heart (13). Animals were treated
with reserpine (0.3 mgykg intraperitoneally every 24 hr) prior
to and during the 4-day antagonist infusion. Reserpine treat-
ment did not prevent up-regulation of the transgene by either
ICI 118,551, alprenolol, or propranolol, and had no effect on
receptor levels per se (data not shown). Thus, catecholamin-
ergic tone is not responsible for the low expression of the
mutated receptor in transgenic animals.
Total RNAwas extracted from the hearts of vehicle- and ICI
118,551-treated transgenic animals, and assayed for transgene
expression. ICI 118,551 treatment did not significantly alter
steady-state levels of transgene mRNA (Fig. 4B). Thus, ligand
effects on gene regulation, if any, do not account for the
measured increase in binding sites ('50-fold).
Increases of membrane b-adrenergic receptor density fol-
lowing treatment with b-adrenergic receptor antagonists have
been observed in laboratory animals and in patients, albeit of
much lower magnitude ('2-fold) (14, 15). In some cases this
increase was shown to be accounted for by the rapid ('60 min)
externalization of an intracellular vesicular pool of receptors
(16). We found, however, that transgenic myocardial prepa-
rations did not contain an appreciable vesicular receptor
population (data not shown), and that the large increase in
membrane receptor density observed in our model cannot be
ascribed to the externalization of a large pool of intracellular
receptors.
We examined whether the effect of drugs on the CAM
b-adrenergic receptor in vivo might be ascribed to some
molecular property of this receptor. In agreement with find-
ings by Gether et al. (8), we found that the CAM b-adrenergic
receptor exhibits a greatly enhanced lability as compared with
the wild-type b2-adrenergic receptor, in particulate prepara-
tions derived from either Sf9 cells (data not shown) or
myocardial tissue from transgenic animals (Fig. 5). This in-
stability is consistent with previous observations that the CAM
b2-adrenergic receptor is expressed at lower levels than the
wild-type receptor in transfected cells (1, 8), and that it is quite
unstable during purification (ref. 8 and unpublished observa-
tions). We thus hypothesized that this instability accounts for
its low steady-state expression levels, both in vivo and in vitro.
Correspondingly, b-adrenergic receptor ligands might be ex-
pected to protect the CAM receptor against decay. In myo-
cardial membranes we found that a representative inverse
agonist (nadolol), a representative antagonist (alprenolol),
and a full agonist (isoproterenol) were all capable of prevent-
ing the loss of binding sites (Fig. 5). Thus, in agreement with
findings in purified Sf9 preparations (8), occupancy of the
receptor by a ligand, irrespective of its efficacy is sufficient to
inhibit or substantially retard the decay of the CAM b2-
adrenergic receptor. This protection presumably causes the
receptor to accumulate in the plasmalemma of myocytes, to
levels similar to what we have previously observed for the
transgenic wild-type b-adrenergic receptor [pmolymg range
(9)]. The much greater receptor up-regulation observed in vivo
(50-fold) than in vitro (2- to 3-fold) presumably relates to the
much higher basal receptor expression levels in the isolated
cells (several pmolymg) compared with the in vivo heart ('100
fmolymg).
Intriguingly, the full agonist isoproterenol is capable of
protecting the receptor in vitro, although it does not up-
regulate it in vivo. Several nonexclusive explanations are
possible. First, the stabilizing effect of agonist ligands on the
receptor may be offset by the well-documented in vivo effects
of agonists to down-regulate the receptors by a variety of
mechanisms. Because this down-regulatory effect of agonists
requires efficacy, the net effect of drug infusion would de-
crease as the efficacy of the drug increases past a threshold
level (marked by pindolol in Fig. 4A). Indeed, isoproterenol
infusion in transgenic animals harboring high levels of the
wild-type receptor [TG33 line (9)] leads to a marked reduction
in receptor levels (data not shown). Second, the dose of agonist
administered in vivo may simply be too low to achieve the
maximal receptor occupancy required for full receptor pro-
tection. Indeed, unlike antagonists that must occupy a large
fraction of receptors to be effective, agonists often require only
a small fractional receptor occupancy for maximum biological
effects. Testing this hypothesis, however, would require lethal
doses of agonists. Third, neuronal and extraneuronal uptake
mechanisms may lower the actual concentration of agonists
substantially.
We demonstrate here that ligand-induced stabilization of a
constitutively active mutant receptor is a novel mechanism for
regulating cellular signaling in vivo. In a sense, the CAM
b2-adrenergic receptor is a molecular switch that is perma-
nently ‘‘on’’ but expressed at such low levels, due to its inherent
instability, that it functions minimally. However, when expres-
sion levels are increased by administration of receptor ligands
that stabilize the protein, cognate physiological pathways
become activated. Thus, signaling is induced by ligands (e.g.,
antagonists), which do not conformationally activate the re-
ceptors, but rather increase their concentration in cell mem-
branes. This unique mechanism for regulating receptor sig-
naling in vivo essentially creates a conditional phenotype and
might be applicable to a broad array of biologically important
molecules. It provides an alternative means for regulating gene
expression, which is often focused at the level of gene tran-
scription (e.g., inducible promoters).
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FIG. 5. Stability of wild-type and CAM b2-adrenergic receptor in
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one-half of the difference of two experiments. (B) Myocardial par-
ticulate preparations of up-regulated CAM transgenic animals ('10
pmolymg) were incubated for 1 hr on ice (08C) or at 378C with no
ligand (378C) or in the presence of either 2 mM nadolol (nad), 100 nM
alprenolol (alp), or 2 mM isoproterenol (iso). Membranes were
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